AiON

Heart failure with preserved ejection fraction

Symptomatic chronic heart failure with an ejection fraction of 50% or above. Tirzepatide (Mounjaro) is not approved for this indication in the EU; data from the SUMMIT trial appear only in section 5.1 of the SmPC.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.